Literature DB >> 14985452

Dual repair modulation reverses Temozolomide resistance in vitro.

Vincent A Barvaux1, Malcolm Ranson, Robert Brown, R Stanley McElhinney, T Brian H McMurry, Geoffrey P Margison.   

Abstract

Temozolomide is an alkylating agent that mediates its cytotoxic effects via O(6)-methylguanine (O(6)-meG) adducts in DNA and their recognition and processing by the postreplication mismatch repair system (MMR). O(6)-meG adducts can be repaired by the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase (MGMT), which therefore constitutes a major resistance mechanism to the drug. Resistance to Temozolomide can also be mediated by loss of MMR, which is frequently mediated by methylation of the hMLH1 gene promoter. Methylation of hMLH1 can be reversed by treatment of cells with 5-aza-2'-deoxycytidine, while the MGMT pseudosubstrate O(6)-(4-bromothenyl)guanine (PaTrin-2) can deplete MGMT activity. Using a drug-resistant cell line which expresses MGMT and has methylated hMLH1, we show that while either of these treatments can individually sensitize cells to Temozolomide, the combined treatment leads to substantially greater sensitization. The increased sensitization is not observed in matched MMR proficient cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985452

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  11 in total

Review 1.  MGMT: a personal perspective.

Authors:  Sankar Mitra
Journal:  DNA Repair (Amst)       Date:  2007-05-07

Review 2.  Management of newly diagnosed glioblastoma: guidelines development, value and application.

Authors:  Jeffrey J Olson; Camilo E Fadul; Daniel J Brat; Srinivasan Mukundan; Timothy C Ryken
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

3.  Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme.

Authors:  Camilo E Fadul; Patrick Y Wen; Lyndon Kim; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

4.  Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.

Authors:  Shaun D Fouse; Jean L Nakamura; C David James; Susan Chang; Joseph F Costello
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

5.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

6.  DNA ligase IV as a new molecular target for temozolomide.

Authors:  Natsuko Kondo; Akihisa Takahashi; Eiichiro Mori; Ken Ohnishi; Peter J McKinnon; Toshisuke Sakaki; Hiroyuki Nakase; Takeo Ohnishi
Journal:  Biochem Biophys Res Commun       Date:  2009-07-15       Impact factor: 3.575

7.  Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.

Authors:  H A Tawbi; J H Beumer; A A Tarhini; S Moschos; S C Buch; M J Egorin; Y Lin; S Christner; J M Kirkwood
Journal:  Ann Oncol       Date:  2012-11-21       Impact factor: 32.976

8.  Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.

Authors:  Elrashied A E Garelnabi; Dimitrios Pletsas; Li Li; Konstantinos Kiakos; Nazira Karodia; John A Hartley; Roger M Phillips; Richard T Wheelhouse
Journal:  ACS Med Chem Lett       Date:  2012-09-18       Impact factor: 4.345

9.  Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53.

Authors:  Dimitrios Pletsas; Elrashied A E Garelnabi; Li Li; Roger M Phillips; Richard T Wheelhouse
Journal:  J Med Chem       Date:  2013-08-16       Impact factor: 7.446

10.  Glioblastoma multiforme therapy and mechanisms of resistance.

Authors:  Yulian P Ramirez; Jessica L Weatherbee; Richard T Wheelhouse; Alonzo H Ross
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.